SG11201406787TA - Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies - Google Patents

Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies

Info

Publication number
SG11201406787TA
SG11201406787TA SG11201406787TA SG11201406787TA SG11201406787TA SG 11201406787T A SG11201406787T A SG 11201406787TA SG 11201406787T A SG11201406787T A SG 11201406787TA SG 11201406787T A SG11201406787T A SG 11201406787TA SG 11201406787T A SG11201406787T A SG 11201406787TA
Authority
SG
Singapore
Prior art keywords
international
laminopathies
singapore
cardiomyopathies
rnai
Prior art date
Application number
SG11201406787TA
Inventor
Colin Stewart
Brian Burke
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG11201406787TA publication Critical patent/SG11201406787TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 24 October 2013 (24.10.2013) WIPOIPCT (10) International Publication Number WO 2013/158046 A1 (51) International Patent Classification: A61K31/7088 (2006.01) A61P 43/00 (2006.01) C12N15/11 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/SG2013/000158 22 April 2013 (22.04.2013) English English (30) Priority Data: 61/687,222 20 April 2012 (20.04.2012) US (71) Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH [SG/SG]; 1 Fusionpolis Way, #20-10 Connexis, Singapore 138632 (SG). (72) Inventors: STEWART, Colin; c/o Institute of Medical Biology, 8A Biomedical Grove, #06-06 Immunos, Singa­ pore 138648 (SG). BURKE, Brian; c/o Institute of Medic­ al Biology, 8A Biomedical Grove, #06-06 Immunos, Singapore 138648 (SG). (74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) (54) Title: RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES B o 00 T-H rn i-H (57) Abstract: The present disclosure relates to inhibitor of Sunl for treatment of laminopathies and to Sunl as markers indicative O of a patient's responsiveness treatment, to enabling improved prediction of a patient's risk, monitoring of laminopathies.
SG11201406787TA 2012-04-20 2013-04-22 Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies SG11201406787TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261687222P 2012-04-20 2012-04-20
PCT/SG2013/000158 WO2013158046A1 (en) 2012-04-20 2013-04-22 Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies

Publications (1)

Publication Number Publication Date
SG11201406787TA true SG11201406787TA (en) 2014-12-30

Family

ID=49383833

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201406787TA SG11201406787TA (en) 2012-04-20 2013-04-22 Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies

Country Status (4)

Country Link
US (1) US20150211004A1 (en)
EP (1) EP2838541A1 (en)
SG (1) SG11201406787TA (en)
WO (1) WO2013158046A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201405991D0 (en) 2014-04-03 2014-05-21 Cambridge Entpr Ltd Novel compounds
EP3636765A1 (en) 2014-04-30 2020-04-15 Tsinghua University Use of tale transcriptional repressor for modulator construction of synthetic gene line in mammalian cells
WO2015165276A1 (en) * 2014-04-30 2015-11-05 清华大学 Reagent kit using tale transcriptional repressor for modular construction of synthetic gene line in mammalian cell
CN104611365B (en) * 2014-07-17 2017-06-16 清华大学 Using TALE Transcription inhibitions built modular synthetic gene circuit in mammalian cell
CN104357422A (en) * 2014-10-08 2015-02-18 绍兴市人民医院 Transcription activator subsample effector nuclease, and coding gene and application thereof
JP7199809B2 (en) * 2015-02-13 2023-01-06 ファクター バイオサイエンス インコーポレイテッド Nucleic acid product and its administration method
US10793601B2 (en) 2016-04-28 2020-10-06 National University Of Singapore Therapeutic spalt-like transcription factor 4 (SALL4) peptide
WO2018035377A1 (en) 2016-08-17 2018-02-22 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
WO2018085198A1 (en) * 2016-11-01 2018-05-11 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
CN110602980B (en) * 2017-05-10 2022-06-28 波士顿科学医学有限公司 Region of interest representation for electroanatomical mapping
EP3740246B9 (en) 2018-01-19 2023-09-27 Agency for Science, Technology and Research Disrupting the linc complex for treating laminopathy
SG10201906637UA (en) * 2019-07-17 2021-02-25 Agency Science Tech & Res Treatment/prevention of disease by linc complex inhibition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006507841A (en) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド Functional and ultrafunctional siRNA
US20120252122A1 (en) * 2011-01-05 2012-10-04 Sangamo Biosciences, Inc. Methods and compositions for increasing production of induced pluripotent stem cells (ipscs)

Also Published As

Publication number Publication date
WO2013158046A1 (en) 2013-10-24
US20150211004A1 (en) 2015-07-30
EP2838541A1 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
SG11201406787TA (en) Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies
SG11201408261UA (en) Syringe
SG11201408303WA (en) Adhesive compositions of propylene-based and ethylene-based polymers
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201407747QA (en) A method and apparatus for facilitating the management of health and security
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201407427WA (en) Extreme pcr
SG11201407233RA (en) Ethylene oligomerization process
SG11201407214RA (en) Position indicator for valves
SG11201408221YA (en) Microstructure-based wound closure devices
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201408119PA (en) Systems and methods for data center cooling and water desalination
SG11201408237YA (en) Compound as wnt signaling inhibitor, composition, and use thereof
SG11201909009TA (en) Catheter securement device with window
SG11201407662WA (en) Process for the preparation of treprostinil and derivatives thereof
SG11201407800SA (en) Selective binding of biological targets to solid phase ureides
SG11201408163VA (en) Modified fibronectin fragments or variants and uses thereof
SG11201408750VA (en) NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
SG11201407635XA (en) Generation of functional and durable endothelial cells from human amniotic fluid-derived cells
SG11201408224SA (en) Novel ruthenium complexes, their use in the metathesis reactions, and a process for carrying out the metathesis reaction